Current Issue

ISSUE 28

Previous

            April - June 2016, Volume 11 No 28 pp 21-28

Table of Contents

About the Cover

Onzetra Xsail is specifically indicated for the acute treatment of migraine with or without aura in adults. It is supplied as a powder for intranasal administration, delivered with the Xsail breath-powered delivery device only. The recommended dose is 22 mg, administered by use of one nosepiece (11 mg) in each nostril. The maximum dose in a 24-hour period should not exceed two doses (44 mg) separated by at least 2 hours (Ref: Vidhya V. FDA Approved Drugs – January 2016. Drug Discovery, 2016, 11(28), 21-22).












COMMUNICATION

Top

FDA Approved Drugs – January 2016

Vidhya V

Onzetra Xsail is specifically indicated for the acute treatment of migraine with or without aura in adults. It is supplied as a powder for intranasal administration, delivered with the Xsail breath-powered delivery device only. The recommended dose is 22 mg, administered by use of one nosepiece (11 mg) in each nostril. The maximum dose in a 24-hour period should not exceed two doses (44 mg) separated by at least 2 hours.

Drug Discovery, 2016, 11(28), 21-22

Full Text | PDF

FDA Approved Drugs – February 2016

Vidhya V

Briviact is specifically indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. It is supplied in three formulations: tablet, oral solution and injection for intravenous administration. The recommended starting dosage is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day).

Drug Discovery, 2016, 11(28), 23-24

Full Text | PDF

FDA Approved Drugs – March 2016

Vidhya V

Taltz (ixekizumab) a humanized interleukin-17A antagonist specifically indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is supplied as an injection for subcutaneous administration. The recommended dose is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.

Drug Discovery, 2016, 11(28), 25-28

Full Text | PDF